CoChat
Sign Up
Cited by 62

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Photodynamic Therapy Activity of New Porphyrin-Xylan-Coated Silica Nanoparticles in Human Colorectal Cancer

Bretin, Ludovic, Pinon, Aline, Bouramtane, Soukaina, Ouk, Catherine, Richard, Laurence, Perrin, Marie-Laure, Chaunavel, Alain, Carrion, Claire, Bregier, Frédérique, Sol, Vincent, Chaleix, Vincent, Leger, David Yannick, Liagre, Bertrand·2019·Cancers
DOI 10.3390/cancers11101474PMC PMC6826978
Open this paper in CoChat — free account

Abstract

Photodynamic therapy (PDT) using porphyrins has been approved for treatment of several solid tumors due to the generation of cytotoxic reactive oxygen species (ROS). However, low physiological solubility and lack of selectivity towards tumor sites are the main limitations of their clinical use. Nanoparticles are able to spontaneously accumulate in solid tumors through an enhanced permeability and retention (EPR) effect due to leaky vasculature, poor lymphatic drainage, and increased vessel permeability. Herein, we proved the added value of nanoparticle vectorization on anticancer efficacy and tumor-targeting by 5-(4-hydroxyphenyl)-10,15,20-triphenylporphyrin (TPPOH). Using 80 nm silica nanoparticles (SNPs) coated with xylan-TPPOH conjugate (TPPOH-X), we first showed very significant phototoxic effects of TPPOH-X SNPs mediated by post-PDT ROS generation and stronger cell uptake in human colorectal cancer cell lines compared to free TPPOH. Additionally, we demonstrated apoptotic cell death induced by TPPOH-X SNPs-PDT and the interest of autophagy inhibition to increase anticancer efficacy. Finally, we highlighted in vivo, without toxicity, elevated anticancer efficacy of TPPOH-X SNPs through improvement of tumor-targeting compared to a free TPPOH protocol. Our work demonstrated for the first time the strong anticancer efficacy of TPPOH in vitro and in vivo and the merit of SNPs vectorization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers11101474

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 In vitro phototoxic effects of 5-(4-hydroxyphenyl)-10,15,20-triphenylporphyrin (TPPOH)-X silica nanoparticles (SNPs)- Photodynamic therapy (PDT) and reactive oxygen species (ROS) production. (A) HT-29 cells were treated or not treated with free TPPOH and TPPOH-X SNPs based on TPPOH concentration. Then, cells were exposed or were not exposed to PDT. Phototoxic effects were determined 48 h post-PDT using the MTT assay. Cell viability, expressed as a percentage of each condition, was compared to controls. IC50 values were calculated using 550.2 nM for TPPOH-X SNPs-PDT and around 6 μM for free TPPOH-PDT. (B) HT-29 cells were treated or not treated with TPPOH-X SNPs and SNPs based on nanoparticles concentration. Then, cells were exposed or not exposed to PDT. Phototoxic effects were determined 48 h post-PDT using the MTT assay. Cell viability, expressed as a percentage of each condition, was compared to controls. (C) HT-29 cells were treated or not treated with free TPPOH or (D) TPPOH-X SNPs with or without NAC co-treatment and then photoactivated or not photoactivated. (E) Comparison of free TPPOH and TPPOH-X SNPs on ROS generation in HT-29 cells. Intracellular ROS levels using DCFDA staining were measured 4 h post-PDT by flow cytometry. A greater right shift implied higher fluorescence intensity resulting from higher amounts of 2’,7’-dichlorofluorescein (DCF) formation and thus greater ROS generation. Data are shown as mean ± SEM (n = 3). ** p < 0.01 and *** p < 0.001.
Figure 1 In vitro phototoxic effects of 5-(4-hydroxyphenyl)-10,15,20-triphenylporphyrin (TPPOH)-X silica nanoparticles (SNPs)- Photodynamic therapy (PDT) and reactive oxygen species (ROS) production. (A) HT-29 cells were treated or not treated with free TPPOH and TPPOH-X SNPs based on TPPOH concentration. Then, cells were exposed or were not exposed to PDT. Phototoxic effects were determined 48 h post-PDT using the MTT assay. Cell viability, expressed as a percentage of each condition, was compared to controls. IC50 values were calculated using 550.2 nM for TPPOH-X SNPs-PDT and around 6 μM for free TPPOH-PDT. (B) HT-29 cells were treated or not treated with TPPOH-X SNPs and SNPs based on nanoparticles concentration. Then, cells were exposed or not exposed to PDT. Phototoxic effects were determined 48 h post-PDT using the MTT assay. Cell viability, expressed as a percentage of each condition, was compared to controls. (C) HT-29 cells were treated or not treated with free TPPOH or (D) TPPOH-X SNPs with or without NAC co-treatment and then photoactivated or not photoactivated. (E) Comparison of free TPPOH and TPPOH-X SNPs on ROS generation in HT-29 cells. Intracellular ROS levels using DCFDA staining were measured 4 h post-PDT by flow cytometry. A greater right shift implied higher fluorescence intensity resulting from higher amounts of 2’,7’-dichlorofluorescein (DCF) formation and thus greater ROS generation. Data are shown as mean ± SEM (n = 3). ** p < 0.01 and *** p < 0.001.CC BY · PubMed Central
Figure 2 Cell uptake of TPPOH-X SNPs by HT-29 cells. (A) HT-29 cells were treated with free TPPOH and TPPOH-X SNPs at 1 μM and cell uptake of these compounds was studied 24 h post-treatment by AMNIS® imaging flow cytometry. The first graph highlights the size/structure of HT-29 cells. After selection of the cell population, TPPOH intensity in HT-29 cells was shown in the second graph and in representative images. The table summarizes the amount of positive TPPOH cells relative to all cells compared to free TPPOH and TPPOH-X SNPs treatments. White scale bar = 10 μm. (B) Representative TEM images of HT-29 cells treated or not treated with TPPOH-X SNPs 24 h post-treatment are shown. Red arrows indicate intracellular nanoparticles. Black scale bar = 1 μm. (C) HT-29 cells were co-treated with TPPOH-X SNPs and LysoTracker or MitoTracker and co-localization was studied 24 h post-treatment by using AMNIS® imaging flow cytometry analysis. The first graph shows TPPOH intensity in HT-29 cells and the second graph shows similarity of TPPOH positive cells compared to LysoTracker or MitoTracker. The table summarizes the amount of TPPOH positive cells co-localized with LysoTracker or MitoTracker. Representative images of co-localization of TPPOH-X SNPs and LysoTracker in HT-29 cells are shown. White scale bar = 10 μm. Data are shown as three independent experiments.
Figure 2 Cell uptake of TPPOH-X SNPs by HT-29 cells. (A) HT-29 cells were treated with free TPPOH and TPPOH-X SNPs at 1 μM and cell uptake of these compounds was studied 24 h post-treatment by AMNIS® imaging flow cytometry. The first graph highlights the size/structure of HT-29 cells. After selection of the cell population, TPPOH intensity in HT-29 cells was shown in the second graph and in representative images. The table summarizes the amount of positive TPPOH cells relative to all cells compared to free TPPOH and TPPOH-X SNPs treatments. White scale bar = 10 μm. (B) Representative TEM images of HT-29 cells treated or not treated with TPPOH-X SNPs 24 h post-treatment are shown. Red arrows indicate intracellular nanoparticles. Black scale bar = 1 μm. (C) HT-29 cells were co-treated with TPPOH-X SNPs and LysoTracker or MitoTracker and co-localization was studied 24 h post-treatment by using AMNIS® imaging flow cytometry analysis. The first graph shows TPPOH intensity in HT-29 cells and the second graph shows similarity of TPPOH positive cells compared to LysoTracker or MitoTracker. The table summarizes the amount of TPPOH positive cells co-localized with LysoTracker or MitoTracker. Representative images of co-localization of TPPOH-X SNPs and LysoTracker in HT-29 cells are shown. White scale bar = 10 μm. Data are shown as three independent experiments.CC BY · PubMed Central
Figure 3 Effects of TPPOH-X SNPs-PDT on HT-29 cell line apoptosis. (A) HT-29 cells were treated or not treated with TPPOH-X SNPs and then photoactivated or not photoactivated. The mitochondrial membrane potential was analyzed by flow cytometry with JC-1 at 48 h post-PDT. R2 represents the aggregate ratio and R3 represents the monomer ratio. (B) HT-29 cells were also stained, 48 h post-PDT, with Annexin V-FITC and PI, and apoptosis was analyzed by flow cytometry. The upper right quadrant represents the percentage of late apoptosis, and the lower right quadrant represents early apoptosis. (C) Caspase-3/7 activity, with the same conditions in HT-29 cells, was evaluated every 2 h during 48 h post-PDT by IncuCyte imaging live cell analysis and green count/cell count/well are shown. Representative images at 48 h post-PDT are shown. Yellow scale bar = 400 μm. (D) DNA fragmentation in HT-29 cells 48 h post-PDT was quantified from cytosol extracts by ELISA. Results are reported as n-fold compared to light control. (E) Representative TEM images of HT-29 cells treated or not treated with TPPOH-X SNPs and photoactivated or not 48 h post-PDT were shown. Red arrows indicate intracellular nanoparticles. Black scale bar = 1 μm. Data are shown as mean ± SEM (n = 3). *** p < 0.001.
Figure 3 Effects of TPPOH-X SNPs-PDT on HT-29 cell line apoptosis. (A) HT-29 cells were treated or not treated with TPPOH-X SNPs and then photoactivated or not photoactivated. The mitochondrial membrane potential was analyzed by flow cytometry with JC-1 at 48 h post-PDT. R2 represents the aggregate ratio and R3 represents the monomer ratio. (B) HT-29 cells were also stained, 48 h post-PDT, with Annexin V-FITC and PI, and apoptosis was analyzed by flow cytometry. The upper right quadrant represents the percentage of late apoptosis, and the lower right quadrant represents early apoptosis. (C) Caspase-3/7 activity, with the same conditions in HT-29 cells, was evaluated every 2 h during 48 h post-PDT by IncuCyte imaging live cell analysis and green count/cell count/well are shown. Representative images at 48 h post-PDT are shown. Yellow scale bar = 400 μm. (D) DNA fragmentation in HT-29 cells 48 h post-PDT was quantified from cytosol extracts by ELISA. Results are reported as n-fold compared to light control. (E) Representative TEM images of HT-29 cells treated or not treated with TPPOH-X SNPs and photoactivated or not 48 h post-PDT were shown. Red arrows indicate intracellular nanoparticles. Black scale bar = 1 μm. Data are shown as mean ± SEM (n = 3). *** p < 0.001.CC BY · PubMed Central
Figure 4 Effects of autophagy inhibition on HT-29 apoptosis. (A) HT-29 cells were treated or not with TPPOH-X SNPs in the presence or absence of 3-MA for 24 h. Expression of autophagy-related proteins was analyzed by Western blotting 48 h post-PDT. β-actin was used as a loading control. Representative images were shown. (B) Representative TEM images of HT-29 cells treated or not with TPPOH-X SNPs 48 h post-PDT protocol are shown. Red arrowheads indicate autophagosomes in the treated cells. Scale bar = 1 μm. (C) HT-29 cells were treated or not with TPPOH-X SNPs with or without 3-MA co-treatment and then were photoactivated or not photoactivated. At 48 h post-PDT, cells were stained with Annexin V-FITC and PI, and apoptosis was analyzed by flow cytometry. Upper right quadrant represents the percentage of late apoptosis, and the lower right quadrant represents early apoptosis. (D) With the same conditions of treatment, caspase-3/7 activity was evaluated each 2 h during 48 h post-PDT protocol by IncuCyte imaging live cell analysis and green count/cell count/well were shown. Representative images at 48 h post-PDT protocol were shown. Yellow scale bar = 400 μm. (E) With the same conditions of treatment, DNA fragmentation was quantified from cytosol extracts with ELISA. Results were reported as n-fold compared to light control. Data are shown as mean ± SEM (n = 3). *** p < 0.001.
Figure 4 Effects of autophagy inhibition on HT-29 apoptosis. (A) HT-29 cells were treated or not with TPPOH-X SNPs in the presence or absence of 3-MA for 24 h. Expression of autophagy-related proteins was analyzed by Western blotting 48 h post-PDT. β-actin was used as a loading control. Representative images were shown. (B) Representative TEM images of HT-29 cells treated or not with TPPOH-X SNPs 48 h post-PDT protocol are shown. Red arrowheads indicate autophagosomes in the treated cells. Scale bar = 1 μm. (C) HT-29 cells were treated or not with TPPOH-X SNPs with or without 3-MA co-treatment and then were photoactivated or not photoactivated. At 48 h post-PDT, cells were stained with Annexin V-FITC and PI, and apoptosis was analyzed by flow cytometry. Upper right quadrant represents the percentage of late apoptosis, and the lower right quadrant represents early apoptosis. (D) With the same conditions of treatment, caspase-3/7 activity was evaluated each 2 h during 48 h post-PDT protocol by IncuCyte imaging live cell analysis and green count/cell count/well were shown. Representative images at 48 h post-PDT protocol were shown. Yellow scale bar = 400 μm. (E) With the same conditions of treatment, DNA fragmentation was quantified from cytosol extracts with ELISA. Results were reported as n-fold compared to light control. Data are shown as mean ± SEM (n = 3). *** p < 0.001.CC BY · PubMed Central
Figure 5 In vivo phototoxic effects on tumor growth. (A) Tumor growth curves of different groups over the treatment period until mouse sacrifice. (B) Representative images of HT-29 tumor-bearing nude mice and ex-vivo tumors after the mice being sacrificed on day 20. Data are shown as mean ± SEM (n = 5). * p < 0.05 and ** p < 0.01.
Figure 5 In vivo phototoxic effects on tumor growth. (A) Tumor growth curves of different groups over the treatment period until mouse sacrifice. (B) Representative images of HT-29 tumor-bearing nude mice and ex-vivo tumors after the mice being sacrificed on day 20. Data are shown as mean ± SEM (n = 5). * p < 0.05 and ** p < 0.01.CC BY · PubMed Central
Figure 6 In vivo antitumor efficacy. (A) Tumors sections from treatment groups at 24 h post-PDT were stained with hematoxylin/eosin/saffron (HES), terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) or LC3 staining. (B) Tumors sections from treatment groups after sacrifice were stained with HES and Ki-67. Representative images of each condition are shown. Black scale bar = 100 μm.
Figure 6 In vivo antitumor efficacy. (A) Tumors sections from treatment groups at 24 h post-PDT were stained with hematoxylin/eosin/saffron (HES), terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) or LC3 staining. (B) Tumors sections from treatment groups after sacrifice were stained with HES and Ki-67. Representative images of each condition are shown. Black scale bar = 100 μm.CC BY · PubMed Central
Figure 7 In vivo and ex vivo fluorescence imaging for biodistribution and safety evaluation. (A) In vivo fluorescence imaging of HT-29 tumor-bearing mice at 24 h post-intravenous injection of Cy5.5-labeled free TPPOH and TPPOH-X SNPs, at 1/100e LD50 for each group. The red circles indicate tumor sites. (B) Ex-vivo fluorescence imaging of tumors and organs at 24 h post-injection. (C) ROI analysis of fluorescence intensity of tumors and organs at 24 h post-injection. (D) Representative images of histological analyses of major organ (kidney, liver, lung, heart and spleen) sections by HES staining. Black scale bar = 100 μm. Data are shown as mean ± SEM (n = 3). * p < 0.05 and NS: not significant.
Figure 7 In vivo and ex vivo fluorescence imaging for biodistribution and safety evaluation. (A) In vivo fluorescence imaging of HT-29 tumor-bearing mice at 24 h post-intravenous injection of Cy5.5-labeled free TPPOH and TPPOH-X SNPs, at 1/100e LD50 for each group. The red circles indicate tumor sites. (B) Ex-vivo fluorescence imaging of tumors and organs at 24 h post-injection. (C) ROI analysis of fluorescence intensity of tumors and organs at 24 h post-injection. (D) Representative images of histological analyses of major organ (kidney, liver, lung, heart and spleen) sections by HES staining. Black scale bar = 100 μm. Data are shown as mean ± SEM (n = 3). * p < 0.05 and NS: not significant.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 61

  1. Xue, 2018, An Update on Colorectal Cancer, Curr. Probl. Surg., 5555, 76, 10.1067/j.cpsurg.2018.02.003 · DOI
  2. Matsuda, 2018, Recent updates in the surgical treatment of colorectal cancer, Ann. Gastroenterol. Surg., 22, 129, 10.1002/ags3.12061 · DOI
  3. Wolpin, 2008, Systemic Treatment of Colorectal Cancer, Gastroenterology, 134134, 1296, 10.1053/j.gastro.2008.02.098 · DOI
  4. Lee, 2018, Molecular targeted therapy: Treating cancer with specificity, Eur. J. Pharmacol., 834, 188, 10.1016/j.ejphar.2018.07.034 · DOI
  5. Xu, 2018, Drug resistance and new therapies in colorectal cancer, World J. Gastroenterol., 2424, 3834
  6. Bugaj, 2016, Photodynamic therapy in colorectal cancer treatment-The state of the art in preclinical research, Photodiagnosis Photodyn. Ther., 13, 158, 10.1016/j.pdpdt.2015.07.175 · DOI
  7. Dolmans, 2003, Photodynamic therapy for cancer, Nat. Rev. Cancer, 33, 380, 10.1038/nrc1071 · DOI
  8. DeRosa, 2002, Photosensitized singlet oxygen and its applications, Coord. Chem. Rev., 233, 351, 10.1016/S0010-8545(02)00034-6 · DOI
  9. Mroz, 2011, Cell Death Pathways in Photodynamic Therapy of Cancer, Cancers, 33, 2516, 10.3390/cancers3022516 · DOI
  10. Plaetzer, 2003, The Modes of Cell Death Induced by PDT: An Overview, Med. Laser Appl., 1818, 7, 10.1078/1615-1615-00082 · DOI
  11. Abrahamse, 2016, New photosensitizers for photodynamic therapy, Biochem. J., 473473, 347, 10.1042/BJ20150942 · DOI
  12. Saini, 2012, Strategies of Targeting Tumors and Cancers, J. Cancer Res. Updates, 1, 129
  13. Huang, 2012, Can nanotechnology potentiate photodynamic therapy?, Nanotechnol. Rev., 11, 111, 10.1515/ntrev-2011-0005 · DOI
  14. Iyer, 2006, Exploiting the enhanced permeability and retention effect for tumor targeting, Drug. Discov. Today, 1111, 812, 10.1016/j.drudis.2006.07.005 · DOI · Paper page
  15. Zhou, 2016, Porphyrin-loaded nanoparticles for cancer theranostics, Nanoscale, 8, 12394, 10.1039/C5NR07849K · DOI
  16. Debele, 2015, Drug Carrier for Photodynamic Cancer Therapy, Int. J. Mol. Sci., 16, 22094, 10.3390/ijms160922094 · DOI
  17. Wu, 2014, Recent Development of Silica Nanoparticles as Delivery Vectors for Cancer Imaging and Therapy, Nanomedicine, 10, 297, 10.1016/j.nano.2013.08.008 · DOI
  18. Couleaud, 2010, Silica-based nanoparticles for photodynamic therapy applications, Nanoscale, 2, 1083, 10.1039/c0nr00096e · DOI
  19. Chen, 2013, In Vivo Bio-Safety Evaluations and Diagnostic/Therapeutic Applications of Chemically Designed Mesoporous Silica Nanoparticles, Adv. Mater., 25, 3144, 10.1002/adma.201205292 · DOI
  20. Lemarchand, 2004, Polysaccharide-decorated nanoparticles, Eur. J. Pharm. Biopharm., 58, 327, 10.1016/j.ejpb.2004.02.016 · DOI
  21. Owens, 2006, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, Int. J. Pharm., 307, 93, 10.1016/j.ijpharm.2005.10.010 · DOI · Paper page
  22. Shrotri, 2017, Chapter Two-Catalytic Conversion of Structural Carbohydrates and Lignin to Chemicals, Adv. Catal., 60, 59, 10.1016/bs.acat.2017.09.002 · DOI
  23. Ma, 2018, Synthesis and characterization of biofunctional quaternized xylan-Fe2O3 core/shell nanocomposites and modification with polylysine and folic acid, Carbohydr. Polym., 199, 382, 10.1016/j.carbpol.2018.07.003 · DOI
  24. Daus, 2010, Xylan-based nanoparticles: Prodrugs for ibuprofen release, Macromol. Biosci., 10, 211, 10.1002/mabi.200900201 · DOI
  25. Bouramtane, 2019, Porphyrin-xylan-coated silica nanoparticles for anticancer photodynamic therapy, Carbohydr. Polym., 213, 168, 10.1016/j.carbpol.2019.02.070 · DOI
  26. Lai, 2014, The significance of autophagy in colorectal cancer pathogenesis and implications for therapy, J. Clin. Pathol., 67, 854, 10.1136/jclinpath-2014-202529 · DOI
  27. Duan, 2018, Ready player one? Autophagy shapes resistance to photodynamic therapy in cancers, Apoptosis, 23, 587, 10.1007/s10495-018-1489-0 · DOI
  28. Hackbarth, 2001, Photophysical properties of pheophorbide-a-substituted diaminobutane poly-propylene-imine dendrimer, Chem. Phys., 269, 339, 10.1016/S0301-0104(01)00337-8 · DOI
  29. Li, 2007, Dendrimer Generation Effects on Photodynamic Efficacy of Dendrimer Porphyrins and Dendrimer-Loaded Supramolecular Nanocarriers, Chem. Mater., 19, 5557, 10.1021/cm071451m · DOI
  30. Roy, 2003, Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: A novel drug-carrier system for photodynamic therapy, J. Am. Chem. Soc., 125, 7860, 10.1021/ja0343095 · DOI
  31. Secret, 2013, Anionic porphyrin-grafted porous silicon nanoparticles for photodynamic therapy, Chem. Commun. (Camb.), 49, 4202, 10.1039/c3cc38837a · DOI
  32. Youssef, 2018, Titania and silica nanoparticles coupled to Chlorin e6 for anti-cancer photodynamic therapy, Photodiagnosis Photodyn. Ther., 22, 115, 10.1016/j.pdpdt.2018.03.005 · DOI
  33. Bharathiraja, 2017, Chlorin e6 conjugated silica nanoparticles for targeted and effective photodynamic therapy, Photodiagnosis Photodyn. Ther., 19, 212, 10.1016/j.pdpdt.2017.06.001 · DOI
  34. Ulbrich, 2018, Silica-based nanoparticles are efficient delivery systems for temoporfin, Photodiagnosis Photodyn. Ther., 21, 275, 10.1016/j.pdpdt.2017.12.014 · DOI
  35. Simon, 2010, Pp IX silica nanoparticles demonstrate differential interactions with in vitro tumor cell lines and in vivo mouse models of human cancers, Photochem. Photobiol., 86, 213, 10.1111/j.1751-1097.2009.00620.x · DOI
  36. Kumar, 2019, Lipophilic 5-fluorouracil prodrug encapsulated xylan-stearic acid conjugates nanoparticles for colon cancer therapy, Int. J. Biol. Macromol., 128, 204, 10.1016/j.ijbiomac.2019.01.101 · DOI
  37. Kumar, 2018, pH-responsive prodrug nanoparticles based on xylan-curcumin conjugate for the efficient delivery of curcumin in cancer therapy, Carbohydr. Polym., 188, 252, 10.1016/j.carbpol.2018.02.006 · DOI
  38. Liu, 2010, Endothelial cells dysfunction induced by silica nanoparticles through oxidative stress via JNK/P53 and NF-kB pathways, Biomaterials, 31, 8198, 10.1016/j.biomaterials.2010.07.069 · DOI
  39. Sergent, 2012, Toxicity and genotoxicity of nano-SiO2 on human epithelial intestinal HT-29 cell line, Ann. Occup. Hyg., 56, 622
  40. Cho, 2009, The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles, Toxicol. Lett., 189, 177, 10.1016/j.toxlet.2009.04.017 · DOI
  41. Kumar, 2010, In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles, ACS Nano, 4, 699, 10.1021/nn901146y · DOI
  42. Chan, 2017, In vivo toxicologic study of larger silica nanoparticles in mice, Int. J. Nanomedicine, 12, 3421, 10.2147/IJN.S126823 · DOI
  43. Liu, 2011, Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice, Biomaterials, 32, 1657, 10.1016/j.biomaterials.2010.10.035 · DOI
  44. Zhou, 1989, Mechanisms of tumor necrosis induced by photodynamic therapy, J. Photochem. Photobiol. B, 3, 299, 10.1016/1011-1344(89)80035-1 · DOI
  45. Elmore, 2007, Apoptosis: A review of programmed cell death, Toxicol. Pathol., 35, 495, 10.1080/01926230701320337 · DOI · Paper page
  46. Skulachev, 1999, Mitochondrial physiology and pathology; concepts of programmed death of organelles, cells and organisms, Mol. Asp.S Med., 20, 139, 10.1016/S0098-2997(99)00008-4 · DOI
  47. Costa, L.D., de Silva, J.A., Fonseca, S.M., Arranja, C.T., Urbano, A.M., and Sobral, A.J.F.N. (2016). Photophysical Characterization and in Vitro Phototoxicity Evaluation of 5,10,15,20-Tetra (quinolin-2-yl) porphyrin as a Potential Sensitizer for Photodynamic Therapy. Molecules, 21. · DOI
  48. Baldea, 2015, Efficiency of photodynamic therapy on WM35 melanoma with synthetic porphyrins: Role of chemical structure, intracellular targeting and antioxidant defense, J. Photochem. Photobiol. B, 151, 142, 10.1016/j.jphotobiol.2015.07.019 · DOI
  49. Liao, 2016, Tetraphenylporphyrin derivatives possessing piperidine group as potential agents for photodynamic therapy, J. Photochem. Photobiol. B, 165, 213, 10.1016/j.jphotobiol.2016.10.031 · DOI
  50. Roby, 2007, Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles, Cancer Biol. Ther., 6, 1136, 10.4161/cbt.6.7.4345 · DOI
  51. Wu, 2019, Self-Luminescing Theranostic Nanoreactors with Intraparticle Relayed Energy Transfer for Tumor Microenvironment Activated Imaging and Photodynamic Therapy, Theranostics, 9, 20, 10.7150/thno.28857 · DOI
  52. Janku, 2011, Autophagy as a target for anticancer therapy, Nat. Rev. Clin. Oncol., 8, 528, 10.1038/nrclinonc.2011.71 · DOI
  53. Xue, 2015, Role of p38MAPK in apoptosis and autophagy responses to photodynamic therapy with Chlorin e6, Photodiagnosis Photodyn. Ther., 12, 84, 10.1016/j.pdpdt.2014.12.001 · DOI
  54. Xiong, 2017, Autophagy inhibition enhances photocytotoxicity of Photosan-II in human colorectal cancer cells, Oncotarget, 8, 6419, 10.18632/oncotarget.14117 · DOI
  55. Wei, 2014, Autophagy promotes resistance to photodynamic therapy-induced apoptosis selectively in colorectal cancer stem-like cells, Autophagy, 10, 1179, 10.4161/auto.28679 · DOI
  56. Tu, 2016, Aloe-emodin-mediated photodynamic therapy induces autophagy and apoptosis in human osteosarcoma cell line MG-63 through the ROS/JNK signaling pathway, Oncol. Rep., 35, 3209, 10.3892/or.2016.4703 · DOI
  57. Zhu, 2018, Inhibition of breast cancer cell growth by methyl pyropheophenylchlorin photodynamic therapy is mediated though endoplasmic reticulum stress-induced autophagy in vitro and vivo, Cancer Med., 7, 1908, 10.1002/cam4.1418 · DOI
  58. Lepage, 2011, Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells, Cancer Lett., 301, 193, 10.1016/j.canlet.2010.12.003 · DOI
  59. Lu, 2010, Biocompatibility, Biodistribution, and Drug-Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals, Small, 6, 1794, 10.1002/smll.201000538 · DOI
  60. Li, 2010, Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model, Eur. J. Cancer., 46, 1900, 10.1016/j.ejca.2010.02.021 · DOI
  61. Liagre, 2017, Analysis of the in vitro and in vivo effects of photodynamic therapy on prostate cancer by using new photosensitizers, protoporphyrin IX-polyamine derivatives, Biochim. Biophys. Acta, 1861, 1676, 10.1016/j.bbagen.2017.02.003 · DOI

Cited by

Sorted by citations

See all 62

Metadata

Authors
Bretin, L., Pinon, A., Bouramtane, S., Ouk, C., Richard, L., Perrin, M.-L., Chaunavel, A., Carrion, C., Bregier, F., Sol, V., Chaleix, V., Leger, D. Y., & Liagre, B.
Venue
Cancers
Publisher
MDPI AG
Published
2019-09-30
Volume
11
Issue
10
Pages
1474
ISSN
2072-6694
DOI
10.3390/cancers11101474
PMC
PMC6826978
Cited by
62
References
2
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review